Cogent Biosciences Q1 net loss $30.6M; cash $191M funds into 2024

Cogent Biosciences, Inc.

2023-Q1 EPS reported -$0.68

Net loss $30.6M in Q1 2022 vs. $11.7M in Q1 2021; R&D spend $25.5M (up from $8.2M).
Cash & equivalents $191.0M as of March 31, 2022, compared to $219.7M at year-end 2021.
Initial APEX Phase 2 data for bezuclastinib in AdvSM to be presented at EHA June 2022.
FGFR2 inhibitor advancing toward IND in H2 2023; ErbB2 mutant selective program announced.
SUMMIT (NonAdvSM) and PEAK (GIST) trials actively enrolling patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.